Fairvoy Private Wealth LLC Has $385,000 Holdings in Merck & Co., Inc. $MRK

Fairvoy Private Wealth LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,865 shares of the company’s stock after selling 390 shares during the period. Fairvoy Private Wealth LLC’s holdings in Merck & Co., Inc. were worth $385,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Barnes Dennig Private Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $27,000. Legend Financial Advisors Inc. acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its stake in shares of Merck & Co., Inc. by 141.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after purchasing an additional 221 shares during the period. MorganRosel Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $36,000. Finally, Fiduciary Wealth Partners LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MRK shares. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Saturday, September 27th. Morgan Stanley dropped their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $106.41.

Merck & Co., Inc. Stock Down 0.3%

MRK stock opened at $89.25 on Friday. The stock’s 50 day simple moving average is $82.87 and its 200 day simple moving average is $81.69. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $111.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The company has a market cap of $222.93 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 0.92 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.6%. Merck & Co., Inc.’s dividend payout ratio is 49.92%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.